Related references
Note: Only part of the references are listed.Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis
Chul Won Jung et al.
LEUKEMIA & LYMPHOMA (2015)
Rationale for combination therapy in myelofibrosis
John Mascarenhas
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2014)
Changing myelofibrosis's natural course at last
Srdan Verstovsek
BLOOD (2014)
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts
Francesco Passamonti et al.
BLOOD (2014)
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study
Paola Guglielmelli et al.
BLOOD (2014)
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
N. Jaekel et al.
BONE MARROW TRANSPLANTATION (2014)
Safety evaluation of ruxolitinib for treating myelofibrosis
Sofia Galli et al.
EXPERT OPINION ON DRUG SAFETY (2014)
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies
Ruben A. Mesa et al.
HAEMATOLOGICA (2014)
Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment
Lana X. Tong et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis
G. Caocci et al.
LEUKEMIA (2014)
JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis
T. Stuebig et al.
LEUKEMIA (2014)
Epidemiology of myeloproliferative neoplasms in the United States
Jyotsna Mehta et al.
LEUKEMIA & LYMPHOMA (2014)
Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
Srdan Verstovsek et al.
ONCOTARGETS AND THERAPY (2014)
Orphan drugs for myelofibrosis
Claire N. Harrison et al.
EXPERT OPINION ON ORPHAN DRUGS (2014)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes et al.
BLOOD (2013)
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy
Claire N. Harrison et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
Srdan Verstovsek et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor
Nicholas G. Wysham et al.
CHEST (2013)
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
Srdan Verstovsek et al.
HAEMATOLOGICA (2013)
A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers
Yoichiro Ogama et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
Ruben A. Mesa et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Population Pharmacokinetic Analysis of Orally-Administered Ruxolitinib (INCB018424 Phosphate) in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET MF)
Xuejun Chen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing
Ruben A. Mesa et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
Moshe Talpaz et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Bilateral Toxoplasmosis Retinitis Associated with Ruxolitinib
Roger A. Goldberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?
Fabio P. S. Santos et al.
Anti-Cancer Agents in Medicinal Chemistry (2012)
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
Srdan Verstovsek et al.
BLOOD (2012)
Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
J. Mascarenhas et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Ruxolitinib In the Treatment of Myelofibrosis
Lily P. H. Yang et al.
DRUGS (2012)
Management of myelofibrosis: a survey of current practice in the United Kingdom
Moosa Rashid Qureshi et al.
JOURNAL OF CLINICAL PATHOLOGY (2012)
The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers
Jack G. Shi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
Ayalew Tefferi et al.
MAYO CLINIC PROCEEDINGS (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
How to manage the transplant question in myelofibrosis
K. Ballen
BLOOD CANCER JOURNAL (2012)
Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers
Jack G. Shi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
Alfonso Quintas-Cardama et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
Ayalew Tefferi et al.
MAYO CLINIC PROCEEDINGS (2011)
Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
Alfonso Quintas-Cardama et al.
BLOOD (2010)
Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans
Adam D. Shilling et al.
DRUG METABOLISM AND DISPOSITION (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms
Stephen T. Oh et al.
EXPERT REVIEW OF HEMATOLOGY (2010)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
A. Tefferi et al.
LEUKEMIA (2008)
Share Paper
